DK2506840T3 - Anvendelser af hæmmere af hypoksi-fremkaldende faktorer - Google Patents

Anvendelser af hæmmere af hypoksi-fremkaldende faktorer Download PDF

Info

Publication number: DK2506840T3
Authority: DK; Denmark
Prior art keywords: hypoxia; inhibitors; inducing factors; inducing; factors
Prior art date: 2009-12-04

Application number

DK10834883.0T

Other languages

English (en)

Inventor

Sami N Malek

Yang Liu

Yin Wang

Yan Liu

Pan Zeng

Original Assignee

Oncoc4 Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-12-04

Filing date

2010-06-25

Publication date

2021-04-12

2010-06-25 Application filed by Oncoc4 Inc filed Critical Oncoc4 Inc

2021-04-12 Application granted granted Critical

2021-04-12 Publication of DK2506840T3 publication Critical patent/DK2506840T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Hematology (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK10834883.0T 2009-12-04 2010-06-25 Anvendelser af hæmmere af hypoksi-fremkaldende faktorer DK2506840T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US26685609P	2009-12-04	2009-12-04
PCT/US2010/039910 WO2011068563A1 (en)	2009-12-04	2010-06-25	Uses of hypoxia-inducible factor inhibitors

Publications (1)

Publication Number	Publication Date
DK2506840T3 true DK2506840T3 (da)	2021-04-12

Family

ID=44115219

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK10834883.0T DK2506840T3 (da)	2009-12-04	2010-06-25	Anvendelser af hæmmere af hypoksi-fremkaldende faktorer

Country Status (15)

Country	Link
US (7)	US9427413B2 (da)
EP (2)	EP2506840B1 (da)
CN (2)	CN109224064A (da)
CA (1)	CA2782527C (da)
CY (1)	CY1125365T1 (da)
DK (1)	DK2506840T3 (da)
ES (1)	ES2864743T3 (da)
HR (1)	HRP20210537T1 (da)
HU (1)	HUE053793T2 (da)
LT (1)	LT2506840T (da)
PL (1)	PL2506840T3 (da)
PT (1)	PT2506840T (da)
SI (1)	SI2506840T1 (da)
SM (1)	SMT202100234T1 (da)
WO (1)	WO2011068563A1 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SMT202100234T1 (it)	2009-12-04	2021-05-07	Oncoc4 Lnc	Usi di inibitori di fattori inducibili da ipossia
CN103007293B (zh) *	2012-12-30	2014-04-02	中国人民解放军第三军医大学第一附属医院	具有靶向性的多肽-基因复合物及其制备方法和应用
EP3337491A4 (en)	2015-08-19	2019-04-10	Children's Research Institute, Children's National Medical Center	COMPOSITIONS AND METHODS FOR TREATING TRANSPLANT HOST REACTION
EP3373910B1 (en)	2015-11-10	2023-07-12	Children's Research Institute, Children's National Medical Center	Echinomycin formulation, method of making and method of use thereof
EP3612177A4 (en) *	2017-04-21	2021-01-13	Lunella Biotech, Inc.	TARGETING HYPOXIC CARCINOUS STEM CELLS (SCC) USING DOXYCYCLINE: IMPLICATIONS FOR IMPROVING ANTI-ANGIOGENIC THERAPY
WO2018195434A1 (en)	2017-04-21	2018-10-25	Lisanti Michael P	Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs)
CA3063717C (en)	2017-05-19	2021-08-24	Lunella Biotech, Inc.	Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
WO2018213764A1 (en)	2017-05-19	2018-11-22	Lunella Biotech, Inc.	Companion diagnostics for mitochondrial inhibitors
BR112019026097A2 (pt)	2017-06-26	2020-07-07	Lunella Biotech, Inc.	mitoketoscins: terapêuticos à base de mitocôndrias com direcionamento no metabolismo da cetona em células cancerígenas
CN110669871A (zh) *	2019-10-17	2020-01-10	河北森朗生物科技有限公司	一种慢病毒转导滴度的测定方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5643871A (en)	1993-11-23	1997-07-01	Bristol-Meyers Squibb Company	Antitumor antibiotics
US6416956B1 (en)	1999-08-13	2002-07-09	George Washington University	Transcription factor, BP1
US7105656B2 (en) *	2000-10-26	2006-09-12	The Brigham And Women's Hospital, Inc.	Compositions and methods for treating hematologic malignancies and multiple drug resistance
NZ543635A (en) *	2003-06-25	2008-05-30	Crucell Holland Bv	Human C-type lectin: a suitable target molecule for binding molecules, particularly immunoconjugates, in the diagnosis, prevention and/or treatment of myeloid neoplastic diseases such as AML and CML
CN1233844C (zh) *	2003-09-05	2005-12-28	上海第二医科大学附属瑞金医院	HIF－1α在治疗白血病药物的筛选中的应用
BRPI0514444A (pt) *	2004-08-27	2008-06-10	Infinity Pharmaceuticals Inc	análogos de ciclopamina e métodos de uso destes
CN101484182B (zh) *	2005-04-06	2014-06-11	Ibc药品公司	由同二聚体、同四聚体或二聚体的二聚体组成的稳定连接复合体的生产方法及用途
US20070212360A1 (en) *	2006-01-17	2007-09-13	Denko Nicholas C	Modulation of mitochondrial oxygen consumption for therapeutic purposes
WO2007130037A1 (en) *	2006-05-02	2007-11-15	Emory University	Hif-1 inhibitors and methods of use thereof
US20080063642A1 (en)	2006-08-02	2008-03-13	Adelman Daniel C	Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of certain hematologic disorders
AU2008240117B2 (en) *	2007-04-13	2013-12-05	Abraxis Bioscience, Llc	SPARC and methods of use thereof
US7867492B2 (en) *	2007-10-12	2011-01-11	The John Hopkins University	Compounds for hedgehog pathway blockade in proliferative disorders, including hematopoietic malignancies
SMT202100234T1 (it)	2009-12-04	2021-05-07	Oncoc4 Lnc	Usi di inibitori di fattori inducibili da ipossia

2010
- 2010-06-25 SM SM20210234T patent/SMT202100234T1/it unknown
- 2010-06-25 SI SI201032066T patent/SI2506840T1/sl unknown
- 2010-06-25 ES ES10834883T patent/ES2864743T3/es active Active
- 2010-06-25 PL PL10834883T patent/PL2506840T3/pl unknown
- 2010-06-25 EP EP10834883.0A patent/EP2506840B1/en active Active
- 2010-06-25 US US13/513,659 patent/US9427413B2/en active Active
- 2010-06-25 HR HRP20210537TT patent/HRP20210537T1/hr unknown
- 2010-06-25 WO PCT/US2010/039910 patent/WO2011068563A1/en not_active Ceased
- 2010-06-25 DK DK10834883.0T patent/DK2506840T3/da active
- 2010-06-25 CN CN201710873182.7A patent/CN109224064A/zh active Pending
- 2010-06-25 CA CA2782527A patent/CA2782527C/en active Active
- 2010-06-25 LT LTEP10834883.0T patent/LT2506840T/lt unknown
- 2010-06-25 CN CN2010800501880A patent/CN102791260A/zh active Pending
- 2010-06-25 EP EP21150064.0A patent/EP3892264A3/en not_active Withdrawn
- 2010-06-25 HU HUE10834883A patent/HUE053793T2/hu unknown
- 2010-06-25 PT PT108348830T patent/PT2506840T/pt unknown
2016
- 2016-08-11 US US15/234,195 patent/US9623070B2/en not_active Expired - Fee Related
2017
- 2017-03-03 US US15/448,737 patent/US9877998B2/en active Active
- 2017-12-12 US US15/839,643 patent/US20180177841A1/en not_active Abandoned
2019
- 2019-03-06 US US16/294,615 patent/US20190255140A1/en not_active Abandoned
2020
- 2020-01-21 US US16/748,455 patent/US20200147167A1/en not_active Abandoned
- 2020-10-13 US US17/069,300 patent/US20210161991A1/en not_active Abandoned
2021
- 2021-04-05 CY CY20211100291T patent/CY1125365T1/el unknown

Also Published As

Publication number	Publication date
HUE053793T2 (hu)	2021-07-28
CY1125365T1 (el)	2024-02-16
HRP20210537T1 (hr)	2021-05-14
CA2782527C (en)	2019-09-17
US9623070B2 (en)	2017-04-18
EP2506840A1 (en)	2012-10-10
CA2782527A1 (en)	2011-06-09
PL2506840T3 (pl)	2021-10-11
US20170035832A1 (en)	2017-02-09
US20210161991A1 (en)	2021-06-03
EP3892264A3 (en)	2021-12-08
EP2506840B1 (en)	2021-01-06
EP3892264A2 (en)	2021-10-13
SMT202100234T1 (it)	2021-05-07
PT2506840T (pt)	2021-04-27
ES2864743T3 (es)	2021-10-14
EP2506840A4 (en)	2013-07-03
US20170239315A1 (en)	2017-08-24
LT2506840T (lt)	2021-06-25
US20190255140A1 (en)	2019-08-22
US20180177841A1 (en)	2018-06-28
US20200147167A1 (en)	2020-05-14
US9427413B2 (en)	2016-08-30
SI2506840T1 (sl)	2021-08-31
CN109224064A (zh)	2019-01-18
US20120264697A1 (en)	2012-10-18
CN102791260A (zh)	2012-11-21
US9877998B2 (en)	2018-01-30
WO2011068563A1 (en)	2011-06-09

Publication	Publication Date	Title
CY2020023I2 (el)	2020-11-25	Αναστολεiς βητα-λακταμασων
DOP2012000114A (es)	2012-08-15	Inhibidor bromodominio de benzodiazepina
SMT201600291B (it)	2016-11-10	Inibitori di proteasi hcv
SMT201600075B (it)	2016-04-29	Composto di diamminocarbossammide eterociclica
EP2485589A4 (en)	2013-02-06	HETEROARYL-BTK INHIBITORS
DK3208269T3 (da)	2021-10-11	Inhibitorer af c-fms-kinase
DK2271642T3 (da)	2014-04-22	Pyridylinhibitorer af hedgehog signalering
SMT201500271B (it)	2016-01-08	Inibitori di neprilisina
SMT201600104B (it)	2016-04-29	Inibitore di bromodominio benzodiazepinico
DK3590934T3 (da)	2021-11-08	Pyrazolylquinoxalinkinasehæmmere
IL225867B (en)	2018-07-31	Coelenterazine substrates
EP2299999A4 (en)	2012-01-25	STAT3 INHIBITORS
DK3357511T3 (da)	2020-08-03	Inhibitorer af t-celleaktivering
SMT201400116B (it)	2014-11-10	Pirimidinoni come inibitori delle PI13K
DK2421825T3 (da)	2014-02-03	Azetidinyldiamider som monoacylglycerollipase-inhibitorer
DK2262793T3 (da)	2012-10-15	Krystallinske former af nilotinib-hci
DK2526425T3 (da)	2014-08-04	Fremgangsmåde til diagnosticering af endometriel receptivitet
EP2399504A4 (en)	2012-12-05	DEVICE FOR INTRODUCING ENDOSCOPE
PL2493466T3 (pl)	2021-11-15	Nowe przeciwguzowe zastosowanie kabazytakselu
DK2358714T3 (da)	2012-08-20	Alkylcyclohexylethere af dihydrotetraazabenzoazulener
DK2260873T3 (da)	2019-09-16	Pcylering af proteiner
EP2456440A4 (en)	2012-12-19	Quinolinone PDE2 INHIBITORS
DK2506840T3 (da)	2021-04-12	Anvendelser af hæmmere af hypoksi-fremkaldende faktorer
BRPI0918564A2 (pt)	2015-12-01	inibidores
DK2111555T3 (da)	2013-09-02	Diagnosticering af præeklampsi